ARCHIVES

Trial In Metastatic Disease To Be Unblinded After Regorafenib Meets Primary Endpoint

This article is from The Cancer Letter archive.

Vol. 34 No. 11 | November 25, 2011

Download PDF Visit The Full Archive

Related Articles

NCI Advisory Group, Other Cancer Meetings For May, June

April 30, 1976

DCBDC Bard Approves Expansion Of SPORE Program To GY Cancers; Okays Two other RFAs

December 4, 1992

In Brief: FDA Oncological Drugs Advisory Committee Gets New Charter, Georgetown’s Schein Is Chairman

October 13, 1978

DCT Board Approves More Than $25 Million In Contract Recompetitions, Two New Contracts

February 23, 1990

Iressa Shrinks Some Lung Tumors, Reduces Symptoms In Phase II Trial

June 28, 2002

President’s Budget Takes Care If R01s, P01s, Fattens Up NTP, Devastates Construction Grants

February 1, 1980